November 12, 2025 4:45pm

After the longest closure in history, the cell and gene therapy (C&GT) sector’s upside got “divided” i.e., burned

There’s nothing wrong in trimming any upside, taking some gains as or before algos and electronic trading “rip” draw more blood from the sector

Pre-open Indication Scoring: 1 Hits and 3 Miss

RMi collects, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trusted and verified intel and share pricing data to bridge the gap to an investment decision

Never leave an investor uninformed!  

A House vote is the remaining hurdle, to the longest government shutdown in US history to an end, but it will take weeks or more before normal operations resume

RMi pre-open: Verisimilitude … https://www.regmedinvestors.com/articles/14192

RMi Research Note: Harvard Apparatus GT (OTCQB): Broke … https://www.regmedinvestors.com/articles/13812  

The past, present and future values of RMi’s analysis sheds light on the cell and gene therapy’s (C&GT) sector’s “current” acrobatics

 

Wednesday: The Dow closed UP +326.86 points or +0.68%, the S&P closed UP +4.31 points or +0.06% while the Nasdaq closed DOWN -61.844 points or -0.26%

  • Theme of the session: a potential end to the record-breaking U.S. government shutdown

Wednesday’s (my) 40-company covered sector’s advance/decline line opened negative with 17 incliners, 22 decliners and 1 flat ending with a negative close of 18 incliners, 22 decliners and 0 flat

Metrics:  Wednesday …

  • The RUT was down -7.48 points or -0.30%,
  • The IWM was down -0.57 or -0.23%;
  • The IBB was up +0.81 points or +0.49%,
  • The NBI was up +11.05 points or +0.20%;
  • The XLV was up +2.14 points or +1.42%,
  • The XBI was up +0.10 points or +0.09% … while
  • The VIX was up +0.22 points or +1.27% at 17.50

 

Q4 – November - 3 positive and 5 negative closes

  • October -1 neutral, 11 positive and 12 negative closes

 

Wednesday Closing UP (10 of 18) 

  • Vertex (VRTX +$4.97 after Tuesday’s +$4.86 and Monday’s +$11.73),
  • BioNTech (BNTX +$3.05 after Tuesday’s +$3.58 and Monday’s +$1.93),
  • IQVIA Holdings (IQV +$2.34 after Tuesday’s +$5.47 and Monday’s +$2.59),
  • Alnylam Pharmaceuticals (ALNY +$0.79 after Tuesday’s +$10.25 and Monday’s -$1.00),
  • Entrada Therapeutics (TRDA +$0.31),
  • Moderna (MRNA +$0.30 after Tuesday’s +$1.17),
  • Ultragenyx Pharmaceuticals (RARE +$0.28 after Tuesday’s +$1.31, Monday’s +$1.31),
  • Compass Therapeutics (CMPX +$0.27),
  • Ionis Pharmaceuticals (IONS +$0.22 after Tuesday’s +$2.91 and Monday’s -$4.01),
  • Solid Biosciences (SLDB +$0.21),

Flat (0)

Wednesday’s Closing DOWN (10 of 22): 

  • CRISPR Therapeutics (CRSP -$3.02),
  • Supernus Therapeutics (SUPN -$1.49),
  • Lenz Therapeutics (LENZ -$0.95 after Tuesday’s +$3.26),
  • uniQure NV (QURE -$0.72 after Tuesday’s +$4.57),
  • Intellia Therapeutics (NTLA -$0.69),
  • Vericel (VCEL -$0.61),
  • Beam Therapeutics (BEAM -$0.61),
  • Prime Medicine (PRME -$0.37),
  • AxoGen (AXGN -$0.37),
  • Capricor Therapeutics (CAPR -$0.33),

 

The Bottom Line: More of the … WHYs

US stocks traded drifting around their records in a mixed session of trading on Wednesday, as cell and gene therapy (C&GT) stocks wobbled

  • As chances grew that the record-long US shutdown will end soon
  • A tale of 2 markets emerged from Tuesday, when the Dow rallied more than 550 points, and the Nasdaq slipped
  • The health care sector was the top-performing sector, driven by advances in names such as Eli Lilly (LLY) and Johnson & Johnson (JNJ). <CNBC>

C&GT sector equities continue to be level share pricing as Q3 earnings release

The week so far:

  • The S&P 500 is up 122.12 points, or 1.8%.
  • The Dow is up 1,267.72 points, or 2.7%.
  • The Nasdaq is up 401.92 points, or 1.7%.
  • The Russell 2000 is up 17.97 points, or 0.7%.

White House press secretary Karoline Leavitt said … hours before the shutdown is likely to end, that economic data delays will likely linger even after the government reopens.

  • It's unclear whether the shutdown's end could open the floodgates for the economic data delayed by the stoppage, key to the Fed's thinking on interest rates.
  • The White House said Wednesday that the October reports on the labor market and inflation would "likely never" be released, since government agencies stopped collecting that data during the shutdown. <Yahoo Finance>

I see mid-week an interruption coming … from earnings expectation and consensus always considering earnings season LPS (loss-per-share).

  • Sector Q3 earnings …
  • Think about it; one of the biggest problems with the cell and gene therapy sector’s share pricing is …  99% of them have no earnings! Revenue from collaborations and runways have become indications of sustainability.
  • I believe earnings per share (EPS) estimates need to be revised along with the response to their share pricing declines upon their release to shake-off pipeline uncertainties
  • Meeting earnings expectation and/or missing consensus will deem share pricing outcomes
  • As earnings evolve, I think it's important to focus on fundamentals, advancing clinical catalysts, “runways” and sector company’s capacity/ability to finance

 

Expectation: Fate Therapeutics (FATE) is expected to post a Q3 loss of $0.29 per share in its upcoming report, which represents a year-over-year change of +27.5%. Revenues are expected to be $0.85 million, down 72.3% from the year-ago quarter.

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

New month, November: understand the “flow” …

New week:

  • 11/12 – Wednesday closed negative with 18 positive, 22 negative and 0 flat
  • 11/11 – Tuesday closed positive with 34 positive, 4 negative and 2 flats
  • 11/10 - Monday closed positive with 26 positive, 14 negative and 0 flats

Last week:

  • 11/7 – Friday closed negative with 16 positive, 24 negative and 0 flat
  • 11/6 – Thursday closed negative with 15 positive, 24 negative and 1 flat
  • 11/5 - Wednesday closed positive with 20 positive, 18 negative and 2 flats
  • 11/4 – Tuesday closed negative with 10 positive, 30 negative and 0 flat
  • 11/3 – Monday closed negative with 10 positive, 26 negative and 4 flats

 

Welcome to my world of defining the “grey’ in our universe!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
  • “I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

 

Why do I keep repeating, framed in a different measurement tool, so investors can make the connection ...

The top three (3) performing in the session:   

  • Wednesday: Vertex (VRTX), BioNTech (BNTX) and IQVIA Holdings (IQV)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), Vertex (VRTX) and IQVIA Holdings (IQV)
  • Monday: Vertex (VRTX), IQVIA Holdings (IQV) and BioNTech (BNTX)

The worst three (3) in the session:

  • Wednesday: CRISPR Therapeutics (CRSP), Supernus Therapeutics (SUPN) and Lenz therapeutics (LENZ)
  • Tuesday: BioLife Solutions (BLFS), MiMedx (MDXG) and CRISPR Therapeutics (CRSP)
  • Monday: Ionis Pharmaceuticals (IONS), uniQure NV (QURE) and Alnylam Pharmaceuticals (ALNY),

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.